Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Aplidine possesses antiviral activity against SARS-CoV-2(IC90 = 0.88 nM). Aplidine is a potent anti-cancer agent by targeting eukaryotic translation elongation factor 1 Alpha 2(EEF1A2, Kd = 80 nM).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 68,500 |
5 mg | 在庫あり | ¥ 167,000 |
10 mg | 在庫あり | ¥ 226,500 |
25 mg | 在庫あり | ¥ 351,500 |
50 mg | お問い合わせ | ¥ 454,500 |
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 305,500 |
説明 | Aplidine possesses antiviral activity against SARS-CoV-2(IC90 = 0.88 nM). Aplidine is a potent anti-cancer agent by targeting eukaryotic translation elongation factor 1 Alpha 2(EEF1A2, Kd = 80 nM). |
ターゲット&IC50 | eEF1A2:80 nM(Kd), SARS-CoV-2:0.88 nM(IC90) |
In vitro | In hACE2-293T cells, Aplidine exhibits anti–SARS-CoV-2 activity with an IC90 of 0.88 nM. In an established model of human pneumocyte-like cells, Aplidine inhibits SARS-CoV-2 replication with an IC90 of 3.14 nM and a selectivity index of 40.4[1]. Aplidine (20 nM; 1 h) induces a dose-dependent decrease in VEGF secretion in MOLT-4 cells. Aplidine (20 nM; 1 h) does not result in significant inhibition of VEGF-R1 mRNA in normal endothelial cells, which do express VEGFR-1 but do not secrete VEGF[1]. |
In vivo | In BALB/c mice expressing human ACE2, Aplidine significantly reduced SARS-CoV-2 infection. 0.3 mg/kg Aplidine group results in a reduction of nearly 2 log units in SARS-CoV-2 viral titers in the lungs, and the 1 mg/kg group leads to a reduction of 1.5 log units[2]. |
分子量 | 1110.34 |
分子式 | C57H87N7O15 |
CAS No. | 137219-37-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (90.06 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Aplidine 137219-37-5 Cell Cycle/Checkpoint DNA Damage/DNA Repair Microbiology/Virology SARS-CoV DNA/RNA Synthesis Inhibitor MOLT-4 SARS coronavirus infection Plitidepsin Leukemia VEGF COVID-19 Antiviral inhibit advanced cancer anticancer Advanced Malignancies inhibitor